Solid tumor/s, Cancer, Urothelial cancer, Bladder cancer
BCYCBicycle Therapeutics plcCatalyst overview
Research summary
This catalyst tracks a Phase 2/3 data readout for Zelenectide pevedotin (zele, formerly BT8009) in Solid tumor/s, Cancer, Urothelial cancer, Bladder cancer. The expected timing is based on the latest available company guidance and may change.
07/30/26:- ASCO Duravelo-2/1 mUC data positive; more Duravelo-2 Ph2 data expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.